Navigation Links
Maxwell Biotech Venture Fund's Portfolio Company Hepatera LLC Announces Start of Phase 2b Clinical Trial of Myrcludex B
Date:3/22/2016

MOSCOW, March 22, 2016 /PRNewswire/ --

Hepatera LLC and its development partner MYR GmbH today announced the initiation of MYR 202, a Phase 2b open label, randomized clinical trial to evaluate efficacy and safety of Myrcludex B in combination with tenofovir in chronically HBV/HDV сo-infected patients. 120 subjects will be enrolled in 20 centers in Russia and Germany.

     (Logo: http://photos.prnewswire.com/prnh/20140213/668442-b )

"We are looking forward to further investigating this novel drug for treatment of the most severe viral hepatitis," said Heiner Wedemeyer, MD, Professor at Hannover Medical School and Chairman of MYR`s Clinical Advisory Board. "Myrcludex B has shown biological activity in the previuos trials and has the potential to become a new option for these difficult-to-treat patients."

"We have discussed the study design with the European and US regulators and hope that the results of the study will build a fundament for a pivotal trial in HDV infection," said Dr. Alexander Alexandrov (Medical Director, MYR GmbH). "In the same time, the study will provide valuable information of the effect of combination therapy on the underlying HBV infection."

About Myrcludex B 

Myrcludex B is a first-in-class entry inhibitor for treatment of chronic hepatitis B and D infections. The drug inhibits the recently identified HBV receptor on the hepatocyte surface and prevents the infection of the healthy cells and viral spreading within the liver.

About Hepatera 

The main activity of the company is the development of safe and effective drugs for the treatment of liver diseases for the Russian market. Myrcludex B is being developed in the framework of international cooperation with the biotechnology company MYR, GmbH (Germany).

About MYR GmbH 

MYR GmbH is a clinical stage biotechnology company focused on drugs for the treatment of chronic hepatitis B and D virus infections. The company was founded in 2010 and is based in Burgwedel, Germany and is supported by investors Maxwell Biotech and High-Tech Gründerfonds (HTGF).

About Maxwell Biotech Venture Fund 

Maxwell Biotech Venture Fund (MBVF) is the first Russian venture fund fully dedicated to investments in the life sciences sector. The fund has been created with the participation of the Russian Venture Company (RVC). MBVF portfolio companies have nine innovative clinical stage drug candidates in development; four thereof are in Phase 2.

Contact:
Hepatera
Yana Delovery, Program Director
Office: +7(495)7265253
e-mail: deloveri@ammaxwell.ru



'/>"/>
SOURCE Maxwell Biotech Venture Fund
Copyright©2016 PR Newswire.
All rights reserved


Related biology technology :

1. The Journal of Allergy and Clinical Immunology Publishes Phase 2a Study Results With Cytos Biotechnologys CYT003 for the Treatment of Allergic Asthma
2. GIN Introduces Advanced Robotics and Dispensing Technology at BVS La Jolla Biotech Day
3. The BioVoyage Institute Now Offering Hands-On Training Programs For Biotechnology Products & Applications
4. Riveting NY Times Bestselling Biotech Thriller, WIRED, Now Only $5.95 for Kindle Owners
5. Animal Biotechnology 2013 Market Report
6. The BioVoyage Institute is seeking the help of corporations, organizations, institutions, communities and individuals to help with bioscience and biotechnology education
7. XBiotech Announces Incorporation Of Its Wholly Owned Subsidiary XBiotech Japan KK
8. BioTechniques: The International Journal of Life Science Methods Announces the Publication of the March 2013 Digital Edition Now Available Online and in the App Store
9. Celladon Corporation To Present at BioCentury Future Leaders in the Biotech Industry Conference
10. Ag-Biotech Offers Male Sterility Locus Marker Services for Breeding Onions
11. UMBC Cybersecurity and Biotechnology Programs Hold April 24 Information Session at Shady Grove Campus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)... ... 11, 2017 , ... The CRISPR-Cas9 system has ... and avoiding the use of exogenous expression plasmids. The simplicity of programming this ... gain-of-function studies. , This complement to loss-of-function studies, such as with RNAi ...
(Date:10/11/2017)... Netherlands and LAGUNA HILLS, Calif. ... Institute of Cancer Research, London (ICR) ... MMprofiler™ with SKY92, SkylineDx,s prognostic tool to risk-stratify patients with ... known as MUK nine . The University of ... which is partly funded by Myeloma UK, and ICR will ...
(Date:10/10/2017)... ... October 10, 2017 , ... ... conjugate (ADC) therapeutics, today confirmed licensing rights that give it exclusive global ... technology developed in collaboration with Children’s Hospital Los Angeles (CHLA). Additionally, ...
(Date:10/10/2017)... ... October 10, 2017 , ... USDM ... firm for the life sciences and healthcare industries, announces a presentation by Subbu ... , The presentation, “Automating GxP Validation for Agile Cloud Platforms,” will present a ...
Breaking Biology Technology:
(Date:4/5/2017)... -- Today HYPR Corp. , leading innovator in ... the HYPR platform is officially FIDO® Certified . ... that empowers biometric authentication across Fortune 500 enterprises and ... 15 million users across the financial services industry, however ... suites and physical access represent a growing portion of ...
(Date:4/4/2017)... NEW YORK , April 4, 2017   ... solutions, today announced that the United States Patent and ... The patent broadly covers the linking of an iris ... the same transaction) and represents the company,s 45 th ... our latest patent is very timely given the multi-modal ...
(Date:3/30/2017)... ANGELES , March 30, 2017  On April ... Hack the Genome hackathon at Microsoft,s ... exciting two-day competition will focus on developing health and ... Hack the Genome is the ... been tremendous. The world,s largest companies in the genomics, ...
Breaking Biology News(10 mins):